Evidence map›Paper›PMID 41318536›Full record

ReviewAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2025

NLRP3 inflammasome expression in pediatric asthma: sputum-based insights, inflammatory mechanisms, and targeted therapeutic strategies.

Mohammed AbuBaha, Samia Aldwaik, Bara Abubaha, Anwar Zahran, Dana Sandouka, Kareem Istetieh, Husam Hamshary, Mohammad Abushehadeh, Sarah Saife, Nadeen Sandoqah

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohammed AbuBahaDepartment of Medicine, An-Najah National University, Nablus, Palestine.
Samia AldwaikDepartment of Medicine, An-Najah National University, Nablus, Palestine. samiaammardweik@gmail.com.
Bara AbubahaDepartment of Medicine, An-Najah National University, Nablus, Palestine.
Anwar ZahranDepartment of Medicine, An-Najah National University, Nablus, Palestine.
Dana SandoukaDepartment of Medicine, An-Najah National University, Nablus, Palestine.
Kareem IstetiehDepartment of Medicine, An-Najah National University, Nablus, Palestine.
Husam HamsharyDepartment of Medicine, An-Najah National University, Nablus, Palestine.
Mohammad AbushehadehDepartment of Medicine, An-Najah National University, Nablus, Palestine.
Sarah SaifeDepartment of Medicine, An-Najah National University, Nablus, Palestine.
Nadeen SandoqahDepartment of Medicine, An-Najah National University, Nablus, Palestine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma is a common chronic inflammatory disease in children. Pediatric asthma has a wide range of immunologic phenotypes and different treatment responses. Recent data from various studies suggest that the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, a cytosolic multiprotein complex, has a central role in innate immunity, may be implicated in pediatric asthma pathogenesis, especially in the neutrophilic corticosteroid-resistant type. This review article investigates the mechanism of NLRP3 inflammasome activation as well as its role in airway inflammation and its expression in pediatric asthma based on sputum studies. The findings emphasize an association between elevated NLRP3 levels and poor asthma control. The need for novel treatments is important because Current using therapies such as corticosteroids and biologics demonstrate variable efficacy. According to data, their efficacy heavily depends on the underlying inflammatory phenotype. Biologics such as mepolizumab, benralizumab, and dupilumab are well known for their corticosteroid-sparing effects especially in cases of severe eosinophilic asthma. even though, their therapeutic benefits are limited when it comes to neutrophilic or steroid-resistant phenotypes. NLRP3 inhibitors are new, promising treatments which emerged recently and show potential capability in reducing airway inflammation in animal models. Furthermore, NLRP3-driven inflammation appears to play a role not only in asthma but also in inflammatory bowel disease and juvenile idiopathic arthritis, indicating a wider relevance for therapies that target the inflammasome pathway. Although promising data, application of this data in clinical practice is still challenging due to many causes, including diagnostic challenges, ethical considerations in trials involving children, and the lack of approved NLRP3 inhibitors for use in children. More research is required and essential to confirm that NLRP3 could be used as a biomarker or therapeutic target in pediatric asthma.

Indexed as

AsthmaImmuneInflammasomeInflammatoryNLRP3PediatricPediatric asthma

Identifiers

PMID41318536
PMCPMC12771812

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.